A Double-Blind, Placebo Controlled, Randomized Trial to Assess the Impact of a Monthly Administration of 50,000 IU of Vitamin D3 for 6 Months on Serum Levels of 25-Hydroxyvitamin D in Healthy Young Adults

Table 3

Percentage of patients whose 25(OH)D levels were found in the <12, 20–30, and >30 ng/mL groups in the vitamin D or placebo group. One patient presented a 25(OH)D level >60 ng/mL in October and another one in May.

	Distribution of 25(OH)D serum levels
	In volunteers receiving vitamin D; Monthly doses of 50,000 IU of cholecalciferol			In volunteers receiving the placebo
25-OH-Vit D	Baseline	After 90 days	After 180 days	Baseline	After 90 days	After 180 days
<12 ng/mL	11.3%	0%	0%	10.5%	42.1%	5.3%
12–19 ng/mL	30.2%	7.6%	3.8%	26.3%	42.1%	28.1%
20–29 ng/mL	47.2%	50.9%	26.4%	49.1%	12.3%	50.9%
≥30 ng/mL	11.3%	41.5%	69.8%	14.0%	3.5%	15.8%